pr ogram 2014...an overview of the innovation days 2013 over 450 participants 31 differents...

An event by

The leading parTnering meeTing in Open innOvaTiOn fOr life ScienceS

www.lifescience-outlook.com/innovationdays

ConferenCes – exhibition hall – one-on-one Partnering Meetings – networking

preliminarYprOgram

2014

OcTOber 6-7, 2014 • pariS, france

5th edition

about the innovation days innovation days aims at connecting healthcare stakeholders and exploring new trends in Open Innovation through valuable discussions and debates. Industry stakeholders and CEO entrepreneurs, academics, key decision makers together with investors and practitioners in intellectual property and Technology Transfer will share best practices, know-how, and strategic orientations in the healthcare international marketplace.

Those forums will be followed by Biotech company presentation tracks, identified as “the most innovative projects” from the Innovation Prize.

innovation days is an essential event for partnering opportunities. participants will maximize qualified alliances thanks to a cutting-edge partnering platform updated and modernized in 2014.

in addition to productive partnering, innovation days offers interactive workshops, panels, company presentations, and a dedicated Innovation Gallery.

innovation days highlights large networking opportunities

innovation prize awarding ceremony interactive panels and workshops featuring experts from the biotech and pharma industry Keynote sessions with executives from biotech and pharma industry leading the way with insights into

business analytics, regulatory, challenges and innovation strategy biotech elevator pitch sessions with presentation from the most innovative companies in key

therapeutic fields

Who will you meet? innovative biotech companies academic researchers &

innovation prize candidates pharmaceutical companies institutional representatives clusters and bioparks investors

an overview of the innovation days 2013 Over 450 participants 31 differents countries represented 35 speakers with conferences, workshops and presentations 40 exhibitors in the exposition hall and the innovation gallery 1050 partnering meetings 6700 messages sent via the partnering platform

innovation days presentation

Cité Internationale Universitaire de Paris17, Boulevard Jourdan • 75014 Paris, France

explore the program

Keynote session meet Universal medica group team for an overview of the future trends in biotech & medtech industry

plenary sessionsindustry analysis, projections and discussion on hot topics accessing innovation: how to build efficient partnerships medical technology and biotechnology: best practices in collaborative research big data revolution: accelerating value and innovation

Speciality forumOffering a deeper dive look at the challenges of e-health: digiTal healTh fOrUm

Tracksperfect for attendees wishing to sample sessions across a variety of topicshow to make a biotech/medTech company successfull? Track 1: innovation financing Track 2: intellectual property Track 3: early market access

p r e l i m i n a r Y p r O g r a m

11:00 - 12:30 Keynote session — innoVAtion MAP 2014

9:45 - 10:30 PlenAry session — Accessing innovation: how to build efficient partnerships

9:30 - 9:45 oPening by UniVersAl MedicA groUP

9:00 REGIsTRaTIOn and welcome coFFee

10:30 - 11:00 networKing breAK & Visit oF tHe eXHibition gAllery

increasing pressure to heighten productivity and lower cost has led many pharma companies to completely rethink their r&d and commercialization strategies. The blueprint is changing—be it by innovative internal structures or through external resources such as m&a or collaborations with vcs, academic institutions, or biotechs. external resources promise new sources of innovation, but also create new challenges for the r&d and commercial teams tasked with delivering approvable, reimbursable and differentiated products at the end of the development process.

Review both early successes and lessons learned from the implementation of novel R&D and commercialization blueprints

Discuss about the arguments for and against such opportunities through collaborations with single external partners and large public private partnerships

Universal medica group will provide a comprehensive overview of the biotech & medtech sector's outlook.

Discussion of clinical data inflection points to expect in 2014

Retrospective look at the field's major financing deals including IPOs, reverse mergers

Follow-on offerings over the past 12 months

Universal medica group will break down for the audience what all of this activity means for the sector's progress, and shed light on the future of both clinical outcomes and investments opportunities for the coming year.

OPEnInnOVaTIOn

FUTUReHEaLTH

12:30 - 14:00 lUncH


mOndaY, Oc TOber 6th, 2014

Sponsored by:

Moderator: Jean deregnAUcoUrt, executive vice president business development, institut Pasteur

Panelists: Zeina AntoUn, clinical research director, glaxosmithKline Patrick KorMAn, vp europe business development, market access and public affairs, Myriad genetics Pascal toUcHon, head of business development & Scientific cooperation, servier

Panelists: rafi MArdAcHti, ceO & president, Universal Medica group


14:00 - 14:45 1 new FUnding soUrces: roAdMAP to A sUccessFUll FinAncing PlAn

14:45 - 15:30 2 UnderstAnding intellectUAl ProPerty

15:30 - 16:15 3 innoVAtion is Also PAtient eMPowerMent

With the shortage of classical venture capital investing and the ongoing boom in early opportunities and strong entrepreneurs, traditional vc is beginning to share the spotlight with alternative models. for therapeutics companies that have already raised some capital or especially those that have products in the clinic, there are some new alternatives to choose from, including option deals, one-product financings from venture capital, and pre-ipO royalty-based financing. foundations, crOs and academic institutions are becoming bigger players as well. Focus on the new approaches to finance early-stage innovation

intellectual property can be a life science company’s most valuable asset-the bedrock that underlines a company’s long-term success. in fact, ip often represents a significant percentage of the overall value of a life science company. being able to maximize the full value of your ip assets while navigating complex third-party ip landscapes is absolutely crucial for success. as a result, the design and implementation of a sound ip strategy must be an essential element of a corporate business model for those in the biotechnology, medical device, diagnostics, and pharmaceutical sectors. Learn about the best way to leverage value from an IP portfolio

lifesciences companies need to significantly extend their business models with more patient-centric value propositions and enduring relationships with patients. indeed, well informed patients and patient advocates have a key role to play in the implementation of patient-centred research strategies, approval process and access to treatments.

This approach will create a cycle of reinvention that will effect the ways in which companies develop products, to how they interface with customers – all of which in the hope to increase r&d productivity, influence behaviors, and radically improve outcomes.

Hear about the reaction of all stakeholders to the idea of an integrated research pathway:

How will such a process work in practice and how do we ensure that the right people are involved at the right time; including the patients?

What is the potential future role of patients in the drug review process?

mOndaY, Oc TOber 6th, 2014Tracks how to make a biotech/medTech company successfull?

InnOVaTIOnFInancInG

InnOVaTIOnManaGEMEnT

PaTIEnTCEnTRICITy

Sponsored by:

Moderator: thierry lAUgel, managing partner, Kls Partners

Panelists: sascha AliVoVic, head of corporate finance and corporate development department, Morphosys david H. donAbediAn, vice president, head of ventures & early Stage collaborations, Abbvie

Moderator: cécile tHeArd-JAllU, partner, Operations division, de gaulle-Fleurance & Associés

Panelists: eric enderlin, patent and Trademark attorney, novagraaf Francine le PecHon-JoUbert, partner, Operations division, de gaulle-Fleurance & Associés

Moderator: giovanna MArsico, director, Patients and web

Panelists: Matthias born, vice president/general manager dc, bd medical We & ema, becton dickinson lode dewUlF, vp, chief patient affairs Officer, Ucb Alexander nAtZ, Secretary general, european confederation of Pharmaceutical entrepreneurs (eUcoPe)


16:30 - 18:00 6th innoVAtion PriZe cereMony

selection criteria

sEaRCH FoR excellence

Scientific quality of innovation

level of intellectual property

Quality of team

project feasibility

chances of success on the market/investor interest

Jury members

Jean deregnaucourt (institut pasteur)

Zeina antoun (glaxoSmithKline)

pascal Touchon (Servier)

patrick Korman (myriad genetics)

chistophe Thurieau (ipsen)

richard pleass (liverpool School of Tropical medicine)

Ola Winqvist (Karolinska institutet)

antony lebeau (agence nationale de la recherche)

maurice chelli (pierre fabre)

cécile Théard (cabinet de gaulle & associés)

The Universal biotech innovation prize confers visibility to promising innovations and aims at facilitating partnership between public and private stakeholders. it is a unique opportunity to identify promising and innovative projects.The Universal biotech innovation prize is open to young innovative companies and to academic researchers.

PreVentiVe And cUrAtiVe tHerAPies MedicAl deVices tecHnologicAl tools

mOndaY, Oc TOber 6th, 2014


18:00 - 19:00 cereMony cocKtAil

THE BEsT InnOVaTIOns


efficient and sustainable healthcare systems, such as e-health, are needed to maintain and improve overall public health. e-health includes efficient exchange of clinical trial data, e-health records and eprescriptions across the iT systems.

This requires interoperable systems for heatlcare professionals, patients/citizens, epidemiologists and pharmaceutical industry. remote access and interoperability allows for mobile health, including smart phones/tablets and social media apps. The use of smart mobile devices will increase the amount of electronically available information and improve therapy compliance.The use of social media augments the power of the public on how new therapies are perceived. and all these support patient empowerment.

Healthcare providers, IT innovators, health leadership, start-ups, hospital officials, group practice managers, investors, entrepreneurs and patients representatives will gather to hear insights, ideas, and analysis from leaders in the health IT community

big data analytics are the future of medicine. This ability to analyze massive quantities of data is key to making personalized medicine the treatment norm. With the deep analyses developed through big data analytics, drug developers can match patients to therapies most likely to work for them, as well as identify new therapeutic approaches. health plans can use the information to develop comparative effectiveness models for specific scenarios and develop more effective and cost-effective approaches to healthcare delivery.

This aspect is being addressed in large consortia organized by big pharmas together with biotech and iT companies.

Let’s find out how they are working and whether they can help get concrete outcomes in terms of use of this data, of handling it and hear about some successful outcomes

09:00 - 10:30 digitAl HeAltH ForUM: bringing disrUPtiVe tecHnologies to Medicine & HeAltHcAre

11:00 - 12:00 PlenAry session — big data revolution: accelerating value and innovation

TUeSdaY, Oc TOber 7th, 2014


E-HEaLTH

BIG DaTa

12:00 - 14:00 lUncH

08:30 REGIsTRaTIOn and welcome coFFee

Panelists: Panos PAPAKonstAntinoU, digital marketing & Sales manager region europe, novartis

Panelists: Mike FUrness, Scientist, dnA nexus


14:00 - 14:45 PLEnaRy sEssIOn — BIOTECH MEETs MEDTECH

While biotechnology is based on biosciences and deals with living organisms and biomolecules, medical technology is a strongly engineer-driven sector that focuses on the development of new equipment. if investments in the medTech sector is growing, the two areas are not always easy to separate. more and more biotech companies are discovering a new market in the medical technology sector, while medTech businesses are using biotech processes to provide ideas for new product innovations.The environment is made more complex as policy makers around the world try to respond to these market forces with reforms and revisions to regulatory regimes.

The panel will discuss how the healthcare industry should best engage with these stakeholders to join the forces of the two sector and develop a workable network that fosters the market access of these innovations for the patients

Join us and meet bioentrepreneurs from the most innovative companies selected by our advisory board (biotech/medTech)!

Participants will have only 5 minutes to pitch their company, product, technology or service to a star-studded panel of pharma BD executives Participants will be judged on the quality and effectiveness of the overall pitch

15:00 - 16:30 PREsEnTInG COMPanIEs

TUeSdaY, Oc TOber 7th, 2014

medical Technology and biotechnology: best practices in collaborative research

MEDTECHFUTURe

PERsPECTIVE

InVEsTOR FoRUm

BIOTECH ELEVaTOR PITCH

Judges: nick dUnscoMbe, head, alliance & integration management, Astrazeneca Frank grAMs, vp, head alliance management & Transactions, sanofi r&d

Panelists: bruce JordAn, international business leader companion diagnostics, roche Professional diagnostics

Sponsors

event organized by

OcTOber 6-8, 2014 • pariS, france

5tH edition

preliminarYprOgram

2014

www.lifescience-outlook.com/innovationdays

Universal Medica Group106, bureaux de la colline92213 Saint-cloud • france+33 (1) 41 12 27 77

rafi mardachti, president & [email protected]

contact for conference program:aurélia ringard, business [email protected]+33 (1) 41 12 27 71

contact for event management:isabelle levasseur, business developer marketing & communication [email protected]+33 (1) 41 12 27 85

contAct For innoVAtion dAys

An eVent by

pr ogram 2014...an overview of the innovation days 2013 over 450 participants 31 differents...

Documents